<DOC>
	<DOCNO>NCT00004193</DOCNO>
	<brief_summary>RATIONALE : ISIS 2503 may kill cancer cell inhibit gene promotes development growth cancer . PURPOSE : Phase II trial study effectiveness ISIS 2503 treat patient metastatic and/or locally recurrent colorectal cancer .</brief_summary>
	<brief_title>ISIS 2503 Treating Patients With Metastatic and/or Locally Recurrent Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate , duration response , time progression patient metastatic and/or locally recurrent adenocarcinoma colon rectum treat ISIS 2503 , antisense inhibitor H-ras . II . Determine safety profile regimen patient . OUTLINE : This multicenter study . Patients receive ISIS 2503 IV continuously 14 day . Courses repeat every 3 week absence disease progression unacceptable toxicity . PROJECTED ACCRUAL : A total 14-25 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic and/or locally recurrent adenocarcinoma colon rectum expect cured standard therapy Patients previously underwent definitive surgical resection subsequently develop metastatic disease diagnosis reconfirm new histologic cytologic specimen : More 5 year elapse since primary surgery OR Primary tumor stage I II At least 1 measurable lesion ( 2 cm wide diameter ) CT MRI scan No CNS metastases PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 0 1 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 1,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin great 1.5 mg/dL Renal : Creatinine great 1.5 mg/dl Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study No underlie disease state associate active bleeding No active infection require therapy No second malignancy within past 5 year except curatively treat nonmelanomatous skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy metastatic disease At least 6 month since prior adjuvant chemotherapy without radiotherapy Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy nonindicator lesion allow recovered See Chemotherapy Surgery : See Disease Characteristics Other : No concurrent approve cancer therapy experimental therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>